tailieunhanh - Báo cáo y học: "New treatment options against gram-negative organisms"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: New treatment options against gram-negative organisms. | Bassetti et al. Critical Care 2011 15 215 http content 15 2 215 CRITICAL CARE REVIEW L_ New treatment options against gram-negative organisms Matteo Bassetti Francesca Ginocchio Malgorzata Mikulska This article is one of eleven reviews selected from the Annual Update in Intensive Care and Emergency Medicine 2011 Springer Verlag and co-published as a series in Critical Care. Other articles in the series can be found online at http series annual. Further information about the Annual Update in Intensive Care and Emergency Medicine is available from http series 8901 Introduction In recent years infections caused by multi-drug resistant MDR pathogens have become a serious problem especially in the nosocomial setting. The World Health Organization WHO has identified antimicrobial resistance as one of the three most important problems for human health. Some authors have summarized this phenomenon with the word ESKAPE to include the most frequent MDR microorganisms Enterococcus faecium Staphylococcus aureus Klebsiella pneumoniae Acinetobacter baumannii Pseudomonas aeruginosa and Enterobacter spp. 1 . Resistance to the current library of antibacterial drugs is a serious problem in all parts of the world including the Asia-Pacific region Latin America Europe and North America. Numerous classes of antimicrobials are currently available for physicians to use in the treatment of patient with infections however the pace of antibiotic drug development has slowed during the last decade Fig. 1 . In particular the pharmaceutical pipeline of antibiotics active against MDR Gram-negative bacteria is very limited. New antibiotics that have been discovered and introduced into clinical practice in the last few years are active mostly against Gram-positive organisms whereas when targeting resistant Gram-negative bacteria clinicians are forced to rediscover old drugs such as polymixins and fosfomycin. Among new antibacterials active against .